Developing therapies – testing to see what helps – making sure what works
EB Study Centre

The EB Study Centre is intensively involved in determining the efficacy, tolerability and safety of new therapeutic approaches for EB. These complex tests are aimed at obtaining marketing authorisation for an effective and safe new therapy.

The research and development of a new therapy involves considerable effort, an extended timeframe and a high level of investments. The first step is to perform laboratory research to ascertain which substances and treatments have a positive and thus soothing effect on disturbed cell mechanisms. After many safety checks and pre-clinical tests have been carried out, a clinical trial can then be initiated, during which patients are allowed to try out the new treatment in accordance with strict guidelines. The effectiveness of the treatment is precisely documented. In order to carry out these trials in a structured and efficient manner, the fourth pillar of the EB House was founded in 2018 – the EB Study Centre.